Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186


PRC2/EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation in situ.

Yu H, Simons DL, Segall I, Carcamo-Cavazos V, Schwartz EJ, Yan N, Zuckerman NS, Dirbas FM, Johnson DL, Holmes SP, Lee PP.

PLoS One. 2012;7(12):e51239. doi: 10.1371/journal.pone.0051239. Epub 2012 Dec 10.


linc-UBC1 physically associates with polycomb repressive complex 2 (PRC2) and acts as a negative prognostic factor for lymph node metastasis and survival in bladder cancer.

He W, Cai Q, Sun F, Zhong G, Wang P, Liu H, Luo J, Yu H, Huang J, Lin T.

Biochim Biophys Acta. 2013 Oct;1832(10):1528-37. doi: 10.1016/j.bbadis.2013.05.010. Epub 2013 May 18.


Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.

Nakagawa S, Okabe H, Sakamoto Y, Hayashi H, Hashimoto D, Yokoyama N, Sakamoto K, Kuroki H, Mima K, Nitta H, Imai K, Chikamoto A, Watanabe M, Beppu T, Baba H.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S667-75. doi: 10.1245/s10434-013-3135-y. Epub 2013 Jul 26.


Polycomb group protein EZH2-mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma.

Wang C, Liu X, Chen Z, Huang H, Jin Y, Kolokythas A, Wang A, Dai Y, Wong DT, Zhou X.

Mol Carcinog. 2013 Mar;52(3):229-36. doi: 10.1002/mc.21848. Epub 2011 Dec 7.


Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.

Liu YL, Gao X, Jiang Y, Zhang G, Sun ZC, Cui BB, Yang YM.

J Cancer Res Clin Oncol. 2015 Apr;141(4):661-9. doi: 10.1007/s00432-014-1854-5. Epub 2014 Oct 19.


Polycomb repressive complex 2 is required for MLL-AF9 leukemia.

Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA.

Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5028-33. doi: 10.1073/pnas.1202258109. Epub 2012 Mar 6.


EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.

Moore HM, Gonzalez ME, Toy KA, Cimino-Mathews A, Argani P, Kleer CG.

Breast Cancer Res Treat. 2013 Apr;138(3):741-52. doi: 10.1007/s10549-013-2498-x. Epub 2013 Mar 29.


Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.

Chen H, Gao S, Li J, Liu D, Sheng C, Yao C, Jiang W, Wu J, Chen S, Huang W.

Oncotarget. 2015 May 30;6(15):13049-59.


High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas.

Ramaglia M, D'Angelo V, Iannotta A, Di Pinto D, Pota E, Affinita MC, Donofrio V, Errico ME, Lombardi A, Indolfi C, Casale F, Caraglia M.

Cancer Cell Int. 2016 Jul 28;16:59. doi: 10.1186/s12935-016-0338-x. eCollection 2016.


Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.

Kong X, Chen L, Jiao L, Jiang X, Lian F, Lu J, Zhu K, Du D, Liu J, Ding H, Zhang N, Shen J, Zheng M, Chen K, Liu X, Jiang H, Luo C.

J Med Chem. 2014 Nov 26;57(22):9512-21. doi: 10.1021/jm501230c. Epub 2014 Nov 12.


Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.

Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA.

Clin Cancer Res. 2006 Feb 15;12(4):1168-74.


Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.

Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I, Yeung KC.

Cancer Res. 2012 Jun 15;72(12):3091-104. doi: 10.1158/0008-5472.CAN-11-3546. Epub 2012 Apr 13.


Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.

Shiogama S, Yoshiba S, Soga D, Motohashi H, Shintani S.

Anticancer Res. 2013 Oct;33(10):4309-17.


Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis.

Hao X, Sun B, Hu L, Lähdesmäki H, Dunmire V, Feng Y, Zhang SW, Wang H, Wu C, Wang H, Fuller GN, Symmans WF, Shmulevich I, Zhang W.

Cancer. 2004 Mar 15;100(6):1110-22.


Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma.

Turner RR, Ollila DW, Krasne DL, Giuliano AE.

Ann Surg. 1997 Sep;226(3):271-6; discussion 276-8.


Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.

Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, Xu J, Guo J.

BJU Int. 2016 Feb;117(2):351-62. doi: 10.1111/bju.12702. Epub 2015 Apr 21.


EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition.

Sun M, Liu XH, Lu KH, Nie FQ, Xia R, Kong R, Yang JS, Xu TP, Liu YW, Zou YF, Lu BB, Yin R, Zhang EB, Xu L, De W, Wang ZX.

Cell Death Dis. 2014 Jun 26;5:e1298. doi: 10.1038/cddis.2014.256.


Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence.

Jeschke U, Mylonas I, Kuhn C, Shabani N, Kunert-Keil C, Schindlbeck C, Gerber B, Friese K.

Anticancer Res. 2007 Jul-Aug;27(4A):1969-74.

Supplemental Content

Support Center